gemcitabine has been researched along with choline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Frese, KK; Griffiths, JR; Jodrell, DI; Madhu, B; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC | 1 |
2 other study(ies) available for gemcitabine and choline
| Article | Year |
|---|---|
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Choline; Deoxycytidine; Diphosphates; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured | 2014 |
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Choline; Choline Kinase; Deoxycytidine; Drug Synergism; Everolimus; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Metabolome; Mice; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |